Eli Lilly and Company, a global healthcare leader, has launched
Humalog 200 units/ml KwikPen (insulin lispro 200 units/m; U-200), the first and only concentrated mealtime insulin analog in the US.
Humalog U-200 KwikPen is a prefilled pen containing a concentrated formulation of Lilly's rapid-acting insulin Humalog (insulin lispro 100 units/ml) to improve glycemic control in people with type 1 and type 2 diabetes. Humalog U-200 KwikPen holds twice as many units of insulin (600 units vs. 300 units) as the U-100 formulation in the same three-milliliter cartridge volume, offering patients a pen that lasts longer, which facilitates fewer pen changes every month.
The most common side effect of Humalog is hypoglycemia (low blood sugar) that may be severe and cause unconsciousness, seizures and death. As with other mealtime insulin pens, Humalog U-200 KwikPen must be used within 28 days after initial use, even if insulin remains. Unused pens should be stored in the refrigerator, but once a pen has been used for the first time, it should be kept at room temperature.
Subscribe to PharmaTutor News Alerts by Email >>
